Core Viewpoint - The report from Simply Wall St highlights that Heptares Therapeutics has experienced a remarkable revenue increase of 243% over the past year, significantly outpacing the industry average growth of 4.1% [1] Financial Performance - Heptares Therapeutics reported a total revenue of approximately 725 million yuan for the first half of the year, representing a year-on-year growth of 327% [1] - The company's profit reached about 523 million yuan, marking a staggering increase of 51 times compared to the previous year [1] - The company has a price-to-earnings ratio of 23, which is below the biotechnology industry average of 52, indicating substantial future growth potential [1] Funding and Financial Stability - Heptares Therapeutics recently raised 517 million HKD through a share placement and repurchased shares worth 121 million HKD [1] - As of June 2025, the company's shareholders' equity is positive, and it has a free cash flow of 49 million USD, positioning the company for continued financial stability [1] Innovation and Market Position - The company's revenue growth has been significantly supported by the licensing and collaboration of innovative products, which are becoming a regular source of income [1] - Heptares Therapeutics has established a strong global collaboration ecosystem based on its industry-leading Harbour Mice® technology platform and its extended 2.0 version technology platform, positioning itself as a "new infrastructure" in global antibody drug development [1]

Core Viewpoint - The company reported significant financial growth in the first half of 2025, with total revenue reaching approximately 725 million RMB (about 101 million USD), representing a year-on-year increase of 327% [1] - Profitability surged to around 523 million RMB (approximately 73 million USD), marking a staggering year-on-year growth of 51 times [1] - The company has a robust cash reserve of about 2.291 billion RMB (around 320 million USD), which is a 92% increase compared to the end of the previous year [1] Financial Performance - Total revenue for the first half of 2025 was approximately 725 million RMB (about 101 million USD), reflecting a 327% year-on-year growth [1] - The profit for the same period was around 523 million RMB (approximately 73 million USD), indicating a year-on-year increase of 51 times [1] - Cash reserves stood at about 2.291 billion RMB (around 320 million USD), which is a 92% increase from the end of last year [1] Strategic Developments - The company achieved several significant milestones in the first half of 2025, showcasing a strong growth trajectory [1] - Revenue growth was significantly driven by the licensing and collaboration of innovative products, which is becoming a regular source of income for the company [1] - The company has successfully transformed its innovation capabilities into sustainable commercial value, demonstrating the effectiveness of its diversified business model, which includes strategic partnerships, licensing, platform collaborations, and innovation incubation [1] Technological Advancements - The company relies on its industry-leading Harbour Mice? technology platform and its extended 2.0 version technology platform to establish a strong global collaboration ecosystem [1] - The company positions itself as a 'new infrastructure' in global antibody drug development [1] - Future plans include deepening source innovation and accelerating the development of the next generation of biotherapies to provide better treatment options for patients worldwide [1]

Core Viewpoint - Heptares Therapeutics reported significant financial growth in the first half of 2025, with total revenue reaching approximately 725 million RMB (about 101 million USD), marking a year-on-year increase of 327% [1] - The company's profit surged to around 523 million RMB (approximately 73 million USD), reflecting a staggering year-on-year growth of 51 times [1] - Cash reserves are robust, totaling about 2.291 billion RMB (around 320 million USD), which is a 92% increase compared to the end of the previous year [1] Financial Performance - Total revenue for the first half of 2025 was approximately 725 million RMB (about 101 million USD), representing a 327% year-on-year growth [1] - Profit for the same period was around 523 million RMB (approximately 73 million USD), showing a year-on-year increase of 51 times [1] - Cash reserves stood at about 2.291 billion RMB (around 320 million USD), up 92% from the end of last year [1] Strategic Insights - The CEO highlighted that the company achieved several significant milestones in the first half of 2025, with profit growth exceeding 50 times, indicating a strong growth trajectory [1] - Revenue growth was significantly driven by the licensing and collaboration of innovative products, which is becoming a regular source of income for the company [1] - The company has successfully transformed its innovation capabilities into sustainable commercial value, demonstrating the effectiveness of its diversified business model, which includes strategic partnerships, licensing, platform collaborations, and innovation incubation [1] Technological Advancements - Heptares Therapeutics has established a strong global collaboration ecosystem based on its industry-leading Harbour Mice® technology platform and its extended 2.0 version technology platform [1] - The company is positioned as a 'new infrastructure' in global antibody drug development, emphasizing its commitment to deepening source innovation and accelerating the development of next-generation biotherapies [1] - The focus remains on providing better treatment options for patients worldwide through innovative therapies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 1 有關Visterra Visterra是一家生物製品研究及早期臨床開發生物技術公司，致力於開發創新抗體 療法，用於治療免疫介導性腎臟疾病及其他難治疾病患者。有關更多資料，請參 閱Visterra的網站( www.visterrainc.com )。 （股份代號：02142） 自願公告 與VISTERRA, INC.訂立授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司全資子公司諾納生物（美國）公司 （「諾納生物」）已與Visterra, Inc.（「Visterra」）訂立授權協議，以利用諾納生物的 專有僅重鏈抗體（「HCAb」）Harbour Mice®技術平台 ...